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ultimately death. The unique and surprising feature is 
that prion diseases are infectious. Yeast prions are de-
rived from proteins differing from the mammalian PrP 
but are also infectious, self propagating proteins which 
typically can convert into an aggregated, amyloidogenic 
form having high beta sheet content. The simple yeast 
organism has served as a valuable model for under-
standing aspects of prion biology, such as prion fi bril 
assembly.  
 Copyright © 2005 S. Karger AG, Basel 
 Yeast Prions 
 How do monomeric prion molecules assemble into ﬁ -
brils? The delicate balance of protein assembly and disas-
sembly was addressed using an elegant model, the yeast 
prion Sup35 (S. Lindquist, Cambridge, Mass., USA). 
Since 1995, it is known that that the heat-shock protein 
HSP104 is required to catalyze Sup35 prion formation in 
yeast, and merely an excess or insufﬁ cient HSP104 abol-
ishes Sup35 oligomers and ﬁ brils  [2] . Lindquist and col-
leagues could now elucidate the mechanism. HSP104 ini-
tiates the formation of the oligomeric intermediate, act-
ing to nucleate the oligomers, but can also break up the 
amyloid ﬁ bers (together with ATP). Thus in high concen-
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 Abstract 
 With the epizootics of bovine spongiform encephalopa-
thy (BSE) in North American cattle, BSE infections in 
goats, new forms of human Creutzfeldt-Jakob disease 
(CJD) and the spread of chronic wasting disease in North 
American deer and elk, one wonders whether we are 
gaining control over the transmissible spongiform en-
cephalopathies (TSEs). Although many basic scientifi c 
questions in the prion fi eld remain hotly debated and 
unresolved  [1] , including the function of the cellular pri-
on protein (PrP), light has been shed on a diverse array 
of topics, and discussions at the latest TSE meeting 
ranged broadly from yeast prion fi bril assembly to mam-
malian prion neurotoxicity to future TSE therapies. Prion 
diseases are protein misfolding disorders which cause 
degeneration of the central nervous system (CNS) and 
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trations of HSP104, the oligomerization and ﬁ bril forma-
tion are extinguished. So in the yeast system, HSP104 
tightly controls the ﬁ brillization and disassembly of the 
Sup35 yeast prion, either promoting ﬁ bril assembly or 
elimination – leading one to wonder whether perhaps 
similar regulatory mechanisms also exist in mammalian 
amyloid formation and elimination. 
 The process of prion aggregation may be determined 
by the amino acid content or the amino acid sequence. 
Wickner et al.  [3] approached this question using another 
yeast prion, namely Ure2p. By shufﬂ ing the domains 
within Ure2p, several constructs were created, all of 
which led to prions and amyloid formation in vitro. 
Therefore, for Ure2p, prions were determined by amino 
acid content, not sequence. This amazing sequence inde-
pendence of the prion domain suggests the formation of 
 parallel , beta-pleated structures. Additionally, deletions 
in the C-terminal domain of Ure2p increased the frequen-
cy of ﬁ bril formation by 100 ! , supporting a model where 
an unknown factor tethers the C-terminal domain, main-
taining a normal conformation. 
 In vertebrates, the situation is more complex, and in 
vitro conversion studies of the mammalian PrP have 
proven crucial. A key ingredient in prion disease devel-
opment is undoubtedly the conversion of the normal 
 cellular PrP into a pathogenic, highly protease-resistant 
isoform that aggregates and forms amyloid ﬁ brils, patho-
logically in the brain. These aggregates lead to neuro-
degeneration and terminal disease. The quintessential 
puzzle has been the nature of the infectious agent: is it 
solely the PrP, or is PrP merely an indispensable compo-
nent of the agent? 
 Prion Conversion in vitro: Scaffolds and Toxic 
Oligomers 
 How is the mammalian PrP converted to the misfold-
ed prion, PrP Sc ? Can we amplify PrP Sc  in vitro to improve 
our diagnostic assay sensitivity? Surachai Supattapone 
(Hanover, N.H., USA) showed an in vitro  prion conver-
sion model in which afﬁ nity-puriﬁ ed preparations of 
PrP C  plus hamster or worm RNA led to impressive in-
creases in the PrP Sc  content. While his original publica-
tion had suggested a sequence speciﬁ city to eukaryotic 
RNA  [4] , he now reported that synthetic PolyA over 45 
base pairs in length, as well as synthetic DNA and poly-
glutamic acid – but not heparin sulfate – also led to in-
creased PrP Sc  as assessed by Western blot, suggesting that 
a variety of polyanions can act as scaffolds for PrP C  con-
version. These scaffolds could serve as an ampliﬁ er of 
PrP Sc  in vivo, although this remains to be shown, but 
these results may also be taken as a hint for amplifying 
prions in vitro which may be exploitable in diagnostic as-
says. 
 Increasingly, studies support oligomeric aggregates as 
the most toxic principle in amyloid diseases. New data 
from Byron Caughey’s group (Hamilton, Mont., USA) 
incriminate a prion oligomer as the most infectious agent 
as well. Using fragmentation and fractionation, the most 
infectious particles/units with the highest converting ac-
tivity were shown to be PrP oligomers, 300–620 kDa in 
size and corresponding to a 14–28 mer of PrP. This im-
portant clue provides a target size for those developing 
interference strategies to disrupt prion conversion. 
 Another hint for therapeutic design may be found in 
the interaction sites for PrP C  and PrP Sc . These sites have 
been mapped (A. Williamson, San Diego, Calif., USA) by 
grafting PrP epitopes onto a human IgG antibody scaffold 
to determine epitopes that precipitate PrP Sc  and infectiv-
ity. The critical components of the interaction were de-
termined to be between PrP amino acids 89–112 and 
136–158. Similar strategies may provide a more detailed 
characterization of the PrP C –PrP Sc  interaction site in the 
future. 
 Location Location Location: Where Does 
Cellular Conversion Take Place? 
 Cellular compartments for prion conversion recog-
nized previously have included the plasma membrane 
and lysosomes, but now we have evidence from D. Har-
ris’ group (Washington University, St. Louis, Mo., USA) 
that the Golgi apparatus may be involved (presented by 
S. Barmada). A transgenic (TG) mouse with a GFP tag at 
the C-terminus of PrP has been generated to investigate 
PrP Sc  localization and trafﬁ cking. Although the PrP-
EGFP was not converted to PrP Sc -EGFP, it nevertheless 
did interact with PrP Sc  intracellularly, and the resulting 
PrP-EGFP:PrP Sc  complex accumulated in the Golgi. Per-
haps the Golgi is another site where PrP converts. Serial 
transmission of these PrP-EGFP:PrP Sc  complexes into 
new PrP-EGFP mice, may result in adaptation and po-
tentially break of the apparent ‘species-barrier’, leading 
to the desired PrP Sc -EGFP. 
 In vitro studies have shown that scrapie infection of 
cells has an acute phase, where prion infection occurs in-
dependently of cell type or TSE strain, which is followed 
by a chronic phase where the cell type and TSE strain are 
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crucial for inducing a persistent infection (S. Priola, Ham-
ilton, Mont., USA). Indeed, the PrP Sc  Western blot band-
ing pattern changes over time in the prion-infected cell 
lines. Additionally, the subcellular compartment for 
 PrP Sc  ampliﬁ cation may differ among cell type. The rep-
lication site as well as other yet unknown cellular factors 
may determine whether a particular cell type supports a 
chronic infection. 
 Neurotoxicity: The Usual Suspects 
 Are we any closer to understanding the mechanism of 
prion neurotoxicity? Cytosolic PrP, proposed as misfold-
ed PrP retrotranslocated into the cytoplasm from the en-
doplasmic reticulum, has been suspected to be a neuro-
toxic intermediate form of PrP  [5, 6] . In vivo evidence of 
this toxicity was presented using a TG mouse model with 
tetracycline inducible expression of a cytosolic PrP (Jiyan 
Ma, Columbus, Ohio, USA). The TG mice developed in-
soluble aggregates from the transgene, cytosolic PrP, 
which could be precipitated, while the endogenous cel-
lular PrP was shown to be soluble. Indeed, the cytosolic 
PrP was toxic to neurons, and the TG mice developed 
neurologic disease. An important mouse line (work in 
progress) expressing a cytosolic version of another GPI-
linked brain protein might prove or disprove the speciﬁ c-
ity of the described PrP toxicity. 
 Another molecular intermediate with neurotoxic prop-
erties is a transmembrane form of PrP,  Ctm PrP, which is 
generated in small amounts and can span the lipid bi-
layer. A TG mouse model of transmembrane prions has 
been produced by David Harris’ group (Washington Uni-
versity, St. Louis, Mo., USA) and, like the mouse with 
cytosolic PrP, also develops neurologic disease (presented 
by R.S. Stewart). Mice that also express wild-type PrP 
demonstrate a loss of cerebellar granular cells, but no mis-
folded PrP Sc . Surprisingly, TG mice on a PrP–/– back-
ground were protected – mice no longer developed neu-
rologic disease or any signs of CNS pathology. In addi-
tion, there was a dose effect seen with co-expression of 
endogenous, wild-type PrP; the higher the PrP expres-
sion, the earlier the neurologic phenotype was observed. 
This ﬁ nding suggested that the  Ctm PrP interferes with the 
function of endogenous PrP. Is transmembrane or cyto-
solic PrP a component of neurotoxicity in natural TSEs? 
Perhaps the neurotoxic species of PrP will be further un-
raveled in future TSE meetings. 
 In vivo Studies Provide Mechanistic Insights 
 The use of TG mouse models has provided a key tool 
to complement in vitro studies of prion disease investiga-
tion. In recent years, in vitro studies have revealed that 
although the majority of PrP is expressed on the cell sur-
face via a GPI linker, a smaller amount of anchorless PrP 
is produced and secreted. To address whether the anchor-
less PrP accelerates or inhibits conversion, a TG mouse 
model that expresses solely GPI-anchorless PrP has been 
generated (B. Chesebro, Hamilton, Mont., USA). Per-
haps surprisingly, exposure of these mice to scrapie prions 
leads to the development of PrP plaques in the brain, but 
without neurologic disease. However, mice that express 
wild-type PrP in addition to the anchorless PrP develop 
scrapie with an accelerated course of disease, showing 
that anchorless PrP contributes to disease. 
 The question of whether PrP glycosylation inﬂ uences 
prion disease was addressed using knock-in mice. PrP has 
two glycosylation sites whose variable occupation results 
in 3 PrP subtypes: unglycosylated, monoglycosylated, or 
diglycosylated. TG mice with absence of either a single 
glycosylation site or both glycosyl moieties were all sus-
ceptible to TSE infection although not to the same extent. 
The glycosylation of host PrP affected the incubation pe-
riod of disease and targeting of pathology within the CNS. 
(J. Manson, Edinburgh, UK). 
 Prion disease in mice, similar to variant CJD or chron-
ic wasting disease, typically has an early lymphoid phase 
where prions accumulate in germinal centers, prior to in-
vasion of the CNS. A recent discovery using several mouse 
models has revealed that prions can also replicate in in-
ﬂ ammatory foci in nonlymphoid organs, such as liver, 
pancreas, or kidney, provided the inﬂ ammation consists 
of tertiary follicles and follicular dendritic cells (A. Aguzzi, 
Zürich, Switzerland). Tertiary follicles generated via lym-
photoxin signaling supported prion replication, whereas 
nonfollicular inﬂ ammation in lymphotoxin knock-out 
animals was devoid of prion replication outside of sec-
ondary lymphoid organs. Indeed, lymphoid follicular in-
ﬂ ammation (via LT signals), deﬁ ned the sites where pri-
ons replicate, and has potential consequences for food 
safety, and implications for prion secretion from inﬂ amed 
organs  [7] . 
 In another aspect of prion pathogenesis, the role of 
DCs in prion transport was addressed using skin scariﬁ -
cation and topical prion exposure (N. Mabbott, Edin-
burgh, UK). In 2 models, Langerhans dendritic cell (LC) 
migration was inhibited using either a CD40L–/– mouse 
or through caspase 1 inhibition. Scrapie infectivity 
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reached the draining lymph node regardless of whether 
LC migration was inhibited or not, suggesting that LCs 
are not major prion transporters. 
 Genetic Features of Prion Diseases 
 To address questions of prion strains and species bar-
riers, several PrP knock-in TG mouse models have been 
generated (J. Manson). Mice with a leucine at PrP codon 
101, mimicking a familial mutation causing Gerstmann-
Sträussler-Scheinker syndrome in humans, did not de-
velop a spontaneous prion disease as seen in humans, but 
the mutation did lead to a decrease in incubation times 
across three species barriers when mice were inoculated 
with hamster 263K, sheep SSBP/1, human Gerstmann-
Sträussler-Scheinker syndrome. 
 Notes from the Field 
 An unusual case of CJD has been reported by Gianlu-
igi Zanusso (Verona, Italy). The patient had no PrP gene 
mutation, PrP genotype at codon 129 (polymorphic site) 
was 129MV heterozygous, MRI was negative for typical 
CJD lesions, and the brain pathology was similar to PrP 
genotype 129VV, with large amounts of intracellular PrP. 
The PrP Sc  Western blot pattern was highly unusual in that 
there was no diglycosylated band. Additionally in Italy, 
an atypical BSE case has been described and designated 
 bovine amyloidogenic spongiform encephalopathy or 
BASE  [8] . This case potentially represents a novel strain 
of bovine prion disease. It has a Western blot glycoform 
pattern with a predominant monoglycosylated band (in 
contrast to diglycosylated band in BSE), an unusual pat-
tern of PrP Sc  accumulation in the brain (for example, 
abundant deposition in the olfactory bulb versus brain-
stem in typical BSE) and an older age distribution in the 
cattle. Mouse inoculation studies are in progress to com-
plete the strain characterization. 
 Improving Our Diagnostics: Progress 
 Recent studies in humans with sporadic CJD have re-
vealed PrP Sc  in the muscle  [9] , presenting a relatively non-
invasive procedure for diagnosing human TSEs without a 
brain biopsy (M. Glatzel, Zürich, Switzerland). Addition-
al work in diagnostics has included attempts to derive a 
prion disease biomarker from large-scale transcriptomic 
analyses of gene expression at different stages of mouse 
scrapie infection (G. Miele, Zürich, Switzerland). Thus far, 
the most profound increase in CNS tissue mRNA (over 
50 ! ) has been associated with the gene for cystatin F. 
 Treatment of Prion Diseases, Reason for Hope 
 Although past studies have conveyed hope for a pos-
sible anti-PrP vaccination and/or antibody therapy, more 
recent data illustrating a strong immunological tolerance 
to PrP  [10] , as well as the potential for unwanted im-
mune-mediated neurotoxic effects, have presented sub-
stantial barriers to these strategies. Indeed, direct brain 
injection of anti-PrP antibodies targeting prion epitope 
90–105 leads to PrP cross-linking and neuronal loss (A. 
Williamson). Therefore, although antibodies may ulti-
mately prove useful for the prevention or treatment of 
prion disease, considerable hurdles have arisen which 
have dampened early enthusiasm  [11] . 
 On a more positive note, surprising results were shown 
using TG mice in which PrP C  expression is ablated at 
  12 weeks of age by endogenous transgene activation (G. 
Mallucci, London, UK). When PrP in neurons is deplet-
ed in mice with established CNS scrapie infection, there 
is reversal of early spongiform degeneration and the mice 
survive long term, despite abundant extraneuronal PrP Sc  
deposition  [12] . This work suggests that PrP depletion 
strategies would be worthwhile to investigate for prion 
disease therapies. 
 Additional hope for treatments stems from studies with 
an inhibitory molecule, PrP-Fc 2 , consisting of a human 
immunoglobin Fc fused to 2 PrP C  molecules (A. Aguzzi). 
Previous published work showed that PrP-Fc 2  prevents 
prion replication in TG mice expressing PrP-Fc 2  and wild-
type PrP  [13] . Follow up studies in wild-type mice have 
revealed that PrP-Fc 2  administered in a lentiviral vector 
at the time of prion inoculation delays prion replication 
and disease. The PrP-Fc 2  lentiviral delivery is planned to 
be submitted for a small-scale phase 1 clinical trial. 
 The multidisciplinary nature of prion science creates 
a charged atmosphere for a meeting, with lively discus-
sions about the basic questions still persisting in the ﬁ eld, 
including the function of the PrP, the mechanism of neu-
rodegeneration and the nature of prion strains. Meetings 
like the one reported here serve as chaperones that bring 
together investigators from various scientiﬁ c disciplines, 
whose interaction may lead to generation of new ideas for 
experiments that will shed light on the fascinating issues 
of prion biology and disease. 
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